Sahr F, Willoughby V R, Gbakima A A, Bockarie M J
College of Medicine and Allied Health Sciences, University of Sierra Leone, Private Mail Bag, Freetown, Sierra Leone.
Ann Trop Med Parasitol. 2001 Jul;95(5):445-9. doi: 10.1080/00034980120072284.
Four cases of Plasmodium falciparum malaria who presented in Sierra Leone in November-December 2000 apparently failed to respond to treatment with artesunate. Three (75%) of the cases fulfilled the World Health Organization's criteria for late treatment failure. Although artesunate ranks only sixth as the first-line drug used by clinicians for the treatment of uncomplicated malaria in Sierra Leone, it is widely sold over the counter in pharmacies in the country. The indiscriminate and injudicious use of artesunate among the Sierra Leonean population is likely to increase the level and frequency of resistance among the local strains of P. falciparum. It is recommended that artesunate be reserved for patients who fail to respond to treatment with another of the antimalarial drugs available. Even then, the artesunate should preferably be used in combination with other, longer-acting antimalarial drugs, to slow the development of further resistance.
2000年11月至12月间在塞拉利昂出现的4例恶性疟原虫疟疾患者,使用青蒿琥酯治疗后明显未见效。其中3例(75%)符合世界卫生组织关于晚期治疗失败的标准。尽管青蒿琥酯在塞拉利昂临床医生用于治疗非复杂性疟疾的一线药物中仅排名第六,但在该国药店却可在柜台随意买到。塞拉利昂民众对青蒿琥酯的滥用和不当使用很可能会提高当地恶性疟原虫菌株的耐药水平和频率。建议将青蒿琥酯留给对其他现有抗疟药物治疗无效的患者。即便如此,青蒿琥酯最好还是与其他作用时间更长的抗疟药物联合使用,以减缓进一步耐药性的产生。